Muscle Recovery After Critical Illness
Launched by KIRBY MAYER · Sep 8, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Muscle Recovery After Critical Illness," is focused on understanding how patients recover their muscle strength and physical function after spending time in the Intensive Care Unit (ICU). Specifically, the study aims to track the recovery journey of ICU survivors, looking at both their physical abilities and the biological markers in their muscles that may affect recovery. Researchers want to find out what helps some people recover well while others may struggle with ongoing weakness or disability even a year after their hospital stay.
To participate in this study, individuals must be adults over 18 years old who were admitted to the ICU for serious conditions like sepsis or acute respiratory failure and stayed there for at least 72 hours. However, those with certain neurological or orthopedic conditions, as well as those who were not able to walk before their ICU stay, are not eligible. Participants can expect to undergo regular assessments to measure their muscle recovery and physical function over time, contributing valuable information that could help improve recovery for future patients. This study is currently recruiting male participants aged 65 to 74.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • adult (\>18 y/o)
- • admission for sepsis or acute respiratory failure with at least 72 hour stay in ICU
- Exclusion Criteria:
- • acute or chronic neurologic condition
- • acute or chronic orthopedic condition preventing strength/functional testing
- • patients who were not ambulatory prior to ICU admission
- • patients not expected to survive \~6months after admission
About Kirby Mayer
Kirby Mayer is a dedicated clinical trial sponsor focused on advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a strong commitment to ethical standards and regulatory compliance, Kirby Mayer collaborates with leading healthcare professionals and institutions to design, implement, and manage clinical trials across various therapeutic areas. The organization emphasizes a patient-centric approach, leveraging cutting-edge technologies and methodologies to ensure the highest quality data collection and analysis. By fostering a culture of collaboration and transparency, Kirby Mayer aims to accelerate the development of safe and effective treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lexington, Kentucky, United States
Birmingham, Alabama, United States
Birmingham, Alabama, United States
Oklahoma City, Oklahoma, United States
Patients applied
Trial Officials
Kirby P Mayer, PhD
Study Director
University of Kentucky
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials